Coronavirus / COVID

July 8th 2025

Invivyd forms the SPEAR Study Group to evaluate pemivibart for Long COVID and post-vaccine syndrome, exploring monoclonal antibody treatment of spike protein.

July 7th 2025

Six health organizations and a physician challenge the legality of rescinded vaccine recommendations and dismissal of federal advisory members.

June 29th 2025

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

June 25th 2025

New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.